Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer

BACKGROUND: Large scale randomized controlled trials have demonstrated that the use of bevacizumab in addition to chemotherapy in patients with advanced non‐small cell lung cancer (NSCLC) conveys significant survival benefits. We explored the clinical impact of a first‐line regimen containing bevaci...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Thorac Cancer
Huvudupphovsmän: Xing, Puyuan, Mu, Yuxin, Wang, Yan, Hao, Xuezhi, Zhu, Yixiang, Hu, Xingsheng, Wang, Hongyu, Liu, Peng, Lin, Lin, Wang, Zhijie, Li, Junling
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons Australia, Ltd 2018
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026612/
https://ncbi.nlm.nih.gov/pubmed/29768721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12650
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk